GT BIOPHARMA INC (GTBP) Forecast, Price Target & Analyst Ratings

NASDAQ:GTBPUS36254L3087

Current stock price

0.4493 USD
-0.02 (-3.38%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GT BIOPHARMA INC (GTBP).

Forecast Snapshot

Consensus Price Target

Price Target
$8.16
+ 1,716.16% Upside

Next Earnings Forecast

Earnings Estimate
Release Date
May 13, 2026
Period
Q1 / 2026
EPS Estimate
-$0.08
Revenue Estimate

ChartMill Buy Consensus

Rating
82.86%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
$8.16
Upside
+ 1,716.16%
From current price of $0.45 to mean target of $8.16, Based on 7 analyst forecasts
Low
$8.08
Median
$8.16
High
$8.40

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

7 Wall Street analysts provided a forecast for the next 12 months for GTBP. The average price target is 8.16 USD. This implies a price increase of 1716.16% is expected in the next year compared to the current price of 0.4493.

Analyst Ratings & History

Current Analyst Ratings

GTBP Current Analyst RatingGTBP Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

GTBP Historical Analyst RatingsGTBP Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
82.86%
GTBP was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about GTBP.
In the previous month the buy percentage consensus was at a similar level.
GTBP was analyzed by 7 analysts. More opinions would make the average more meaningful.

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2024-12-02Roth MKMInitiate Buy
2023-08-08HC Wainwright & Co.Reiterate Buy -> Buy
2023-08-07EF HuttonReiterate Hold -> Hold
2023-06-05HC Wainwright & Co.Reiterate Buy -> Buy
2023-05-17HC Wainwright & Co.Reiterate Buy -> Buy
2023-05-16EF HuttonReiterate Hold -> Hold
2023-04-03HC Wainwright & Co.Reiterate Buy
2023-03-31EF HuttonReiterate Hold
2023-01-05EF HuttonInitiate Hold
2022-09-13HC Wainwright & Co.Maintains Buy
2021-05-24HC Wainwright & Co.Initiate Buy
2021-04-13B. Riley FBRInitiate Buy
2021-03-17Roth CapitalInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 13, 2026
Period
Q1 / 2026
EPS Estimate
-$0.08
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
75.27%
Number of Analysts
3

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

GTBP is expected to report earnings on 5/13/2026. The consensus EPS estimate for the next earnings is -0.08 USD and the consensus revenue estimate is 0 USD.

Full Analyst Estimates 2026 - 2031

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031
Revenue
YoY % growth
GTBP revenue by date.GTBP revenue by date.
27KN/A
-100.00%
N/AN/AN/A20.474B64.804B
216.52%
97.626B
50.65%
EBITDA
YoY % growth
GTBP ebitda by date.GTBP ebitda by date.
-8.925MN/A
-5.02%
N/A
-1,346.37%
N/A
84.11%
N/A
46.85%
N/A
40.94%
N/AN/AN/A-14.526B-14.388B
0.95%
-14.753B
-2.54%
-15.133B
-2.57%
N/AN/AN/AN/A
EBIT
YoY % growth
GTBP ebit by date.GTBP ebit by date.
-8.927MN/A
-5.01%
N/A
-1,346.23%
N/A
84.10%
N/A
46.85%
-6.222M
40.96%
-47.086M
-750.31%
-21.639M
63.04%
-14.224M
36.13%
-14.526M
-5.80%
-6.692M
53.41%
-10.784M
-61.15%
-11.044M
-2.40%
-11.314M
-2.45%
4.352M
138.47%
48.359M
1,011.19%
80.852M
67.19%
Operating Margin
GTBP operating margin by date.GTBP operating margin by date.
-33,062.96%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A0.02%0.07%0.08%
EPS
YoY % growth
GTBP eps by date.GTBP eps by date.
N/AN/AN/AN/AN/A-6.89-51.71
-1,063.40%
-20.04
74.91%
-6.12
71.19%
-6.93
-19.62%
-1.69
76.03%
-0.71
56.99%
-0.53
25.71%
-1.10
-107.69%
-0.26
76.85%
0.57
324.00%
N/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26
EPS
Q2Q % growth
-0.08
75.27%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
N/A
EBIT
Q2Q % growth
-2.563M
-32.67%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

GTBP Yearly Revenue VS EstimatesGTBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2029 2030 2031 20B 40B 60B 80B
GTBP Yearly EPS VS EstimatesGTBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
10.15%
EPS Next 5 Year
18.58%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
-913.74%
EBIT Next 5 Year
N/A

GT BIOPHARMA INC / GTBP Forecast FAQ

Can you provide the average price target for GT BIOPHARMA INC stock?

7 analysts have analysed GTBP and the average price target is 8.16 USD. This implies a price increase of 1716.16% is expected in the next year compared to the current price of 0.4493.

When does GT BIOPHARMA INC (GTBP) report earnings?

GT BIOPHARMA INC (GTBP) will report earnings on 2026-05-13.

What are the consensus estimates for GT BIOPHARMA INC (GTBP) next earnings?

The consensus EPS estimate for the next earnings of GT BIOPHARMA INC (GTBP) is -0.08 USD and the consensus revenue estimate is 0 USD.

What is the consensus rating for GT BIOPHARMA INC (GTBP) stock?

The consensus rating for GT BIOPHARMA INC (GTBP) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.